Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 23,928 followers.

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation https://t.co/Yi03pVgKsM https://t.co/Ir8RjdzqSF

04 Nov 2022

Reply Repost Favourite

19 Oct 2022

Reply Repost Favourite

New research: Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation: Background Renal pelvic urothelial… https://t.co/NE

18 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.